Nephrotoxicity associated with Orlistat in normal and obese female rats | ||||
| Journal of Bioscience and Applied Research | ||||
| Article 3, Volume 4, Issue 3, September 2018, Page 193-198 PDF (239.31 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jbaar.2018.148655 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ehab Tousson; Ahmed Massoud; Attyat Salem; Shahenda A. Fatoh 
| ||||
| Department of Zoology, Faculty of Science, Tanta University, Tanta, Egypt | ||||
| Abstract | ||||
| Obesity is a global health concern associated with high morbidity and mortality. Therapeutic strategies include synthetic drugs and surgery, which may entail high costs and serious complications. Orlistat is a pancreatic lipase inhibitor licensed for the treatment of obesity. The current study was carried out to elucidate the modulating effect of Orlistat against obesity-induced kidney toxicity in female rats. A total of 50 female rats were divided into five groups (G1, Control; G2, Orlistat; G3, Obesity; G4, Co- treated Orlistat with Obesity; G5, Post- treated Obesity with Orlistat rat group). The current study revealed that a significant increase in serum urea, creatinine, while a significant decrease in the levels of sodium, potassium, calcium, and chloride ions levels in treated rats with Orlistat while a significant increase in serum urea, creatinine, sodium, potassium, and chloride ions levels in obesity group when compared with a control group. In contrast; a significant decrease in serum urea, Creatinine, sodium, potassium, and chloride ions levels in treated obese rats with Orlistat when compared with the obesity group. So; Orlistat-induced renal toxicity when used for the treatment of obesity and self-recovered obese rats is safe and better than the use of Orlistat in the treatment of obesity. | ||||
| Keywords | ||||
| Obesity; Orlistat; kidney functions; Electrolytes; Toxicity; Rat | ||||
|
Statistics Article View: 157 PDF Download: 231 |
||||
